Simvastatin proves to be helpful in parkinson's disease
According to a study conducted at Rush University Medical Center, FDA-approved medication simvastatin commonly used to lower cholesterol level may prevent parkinson's disease from progressing further. The study was conducted on mice with parkinson's disease which showed that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease.
The study have shown that the activity of one protein called p21Ras increases very early in the midbrain of mice with parkinson's pathology. Simvastatin enters into the brain and blocks the activity of the p21Ras protein and other associated toxic molecules and goes on to protect the neurons, normalizes the neurotransmitter levels there byimproves the motor functions in the mice with parkinson's. Researchers said that if these results are successfully replicated in parkinson's patients in the clinical setting then it would be a remarkable advance in the treatment of this devastating neurodegenerative disease.
Parkinson's disease affects about 1.2 million patients in the United States and Canada. Although 15 percent of patients are diagnosed before age 50, it is generally considered a disease that targets older adults, affecting one of every 100 persons over the age of 60.